Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Adoptive Cell Therapy Across Cancer Diagnoses

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: Autologous tumor-infiltrating lymphocytes
Drug: Ipilimumab
Drug: Nivolumab
Drug: proleukin
Drug: Cyclophosphamide
Drug: Fludara

First Posted Date: 2017-09-28

Last Posted Date: 2024-10-26

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 25

Registration Number: NCT03296137

Locations: 🇩🇰
Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Phase 2

Completed

Conditions: Malignant Neoplasm of Breast

Interventions: Drug: Pembrolizumab
Drug: nab-paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2017-09-21

Last Posted Date: 2021-04-08

Lead Sponsor: Institut fuer Frauengesundheit

Target Recruit Count: 53

Registration Number: NCT03289819

Locations: 🇩🇪
Department of Gynecology, Tübingen University Hospital, Tübingen, Baden-Württemberg, Germany
🇩🇪
Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH, Berlin, Germany
🇩🇪
Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH, Bottrop, North Rhine-Westphalia, Germany

and more 1 locations

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1

Completed

Conditions: Metastatic Ovarian Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: TIL infusion
Drug: Interleukin-2
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-09-19

Last Posted Date: 2023-03-01

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 7

Registration Number: NCT03287674

Locations: 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Phase 1

Withdrawn

Conditions: Breast Cancer
Cancer of Breast

Interventions: Biological: MCS110
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Procedure: Bone marrow aspirate
Procedure: Peripheral blood samples
Procedure: Tumor tissue

First Posted Date: 2017-09-18

Last Posted Date: 2018-08-16

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03285607

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Phase 2

Recruiting

Conditions: Childhood Cancer
Acute Lymphoblastic Leukemia
Down Syndrome

Interventions: Drug: Daunorubicin
Drug: Prednisolone
Drug: Vincristine
Drug: Epirubicin
Drug: E-coli L-asparaginase
Drug: 6-Mercaptopurine
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine
Drug: Cyclophosphamide

First Posted Date: 2017-09-18

Last Posted Date: 2022-09-28

Lead Sponsor: National Hospital Organization Nagoya Medical Center

Target Recruit Count: 60

Registration Number: NCT03286634

Locations: 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Subang Jaya, Malaysia

and more 7 locations

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase 1

Active, not recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Drug: Fludarabine Phosphate

First Posted Date: 2017-09-11

Last Posted Date: 2024-06-12

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT03277729

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine Placebo
Drug: Polatuzumab vedotin Placebo

First Posted Date: 2017-09-07

Last Posted Date: 2025-01-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03274492

Locations: 🇷🇺
Leningrad Regional Clinical Hospital, St Petersburg, Sankt Petersburg, Russian Federation
🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 213 locations

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Phase 2

Conditions: Neoplasms, Breast

Interventions: Biological: Trastuzumab
Drug: Lapatinib
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2017-09-06

Last Posted Date: 2017-09-06

Lead Sponsor: Xijing Hospital

Target Recruit Count: 100

Registration Number: NCT03273595

Locations: 🇨🇳
Xijing Hospital, Xi'an, Shanxi, China

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Perjeta Injectable Product
Drug: Herceptin
Drug: Tamoxifen
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Leuporelin acetate
Drug: Leuprorelin acetate
Drug: Goserelin
Diagnostic Test: Biopsy
Procedure: Surgery

First Posted Date: 2017-09-05

Last Posted Date: 2024-04-17

Lead Sponsor: Palleos Healthcare GmbH

Target Recruit Count: 257

Registration Number: NCT03272477

Locations: 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Grade 1 Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy
Drug: Bendamustine Hydrochloride
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Lenalidomide
Drug: Cyclophosphamide
Biological: Obinutuzumab
Drug: Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Drug: Umbralisib
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2017-09-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT03269669

Locations: 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸
Banner McKee Medical Center, Loveland, Colorado, United States

and more 430 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy